首页> 美国卫生研究院文献>BMC Cancer >Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging
【2h】

Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging

机译:新诊断胶质母细胞瘤的剂量多中心III期临床试验:SPECTRO-GLIO试验比较了A组标准放射化学疗法与B组放射化学疗法以及MR光谱成像引导的同时集成增强

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundGlioblastoma, a high-grade glial infiltrating tumor, is the most frequent malignant brain tumor in adults and carries a dismal prognosis. External beam radiotherapy (EBRT) increases overall survival but this is still low due to local relapses, mostly occurring in the irradiation field. As the ratio of spectra of choline/N acetyl aspartate> 2 (CNR2) on MR spectroscopic imaging has been described as predictive for the site of local relapse, we hypothesized that dose escalation on these regions would increase local control and hence global survival.
机译:背景胶质母细胞瘤是一种高度的神经胶质浸润性肿瘤,是成人中最常见的恶性脑肿瘤,预后不良。外部束放射疗法(EBRT)可以提高总体存活率,但是由于局部复发(大多数发生在照射场中),该率仍然很低。由于已描述了MR光谱成像中胆碱/ N乙酰天冬氨酸N> 2(CNR2)的光谱比可预测局部复发的部位,因此我们假设这些区域的剂量升高将增加局部控制,从而提高整体生存率。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号